![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Medgenics Inc 11 May 2008 Medgenics, Inc. ("Medgenics" or the "Company") MEDGENICS TO PRESENT AT RODMAN & RENSHAW 5th ANNUAL GLOBAL HEALTHCARE CONFERENCE Misgav, Israel and London, UK - 12 May 2008 - Medgenics (AIM: MEDG), the US-incorporated biopharmaceutical company developing the 'biopump' sustained-action protein therapy for the treatment of chronic diseases, announces that Andrew L. Pearlman, Ph.D., President and CEO, is scheduled to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference. The conference will be held 19-20 May at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Dr. Pearlman will present on Monday 19 May at 3:10 p.m. in the Atlantique Salon. Dr. Pearlman will provide an introduction to Medgenics and its innovative ' biopump' technology, as well as providing an update on progress towards the start of its Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy for producing and delivering erythropoietin (EPO) to treat anaemia. A live webcast of Medgenics' presentation can be accessed by logging onto http://www.wsw.com/webcast/rrshq10/medgenics/. For further information, contact: Medgenics, Inc. Phone: +972 4 902 8900 Dr. Andrew L. Pearlman Citigate Dewe Rogerson Phone: +44 207 638 9571 Dr. Mark Swallow Jonathan Shillington (Global Consulting Group) Blomfield Corporate Finance Limited Phone: +44 207 512 0191 James Pinner Alan MacKenzie NOTES TO EDITORS: About Medgenics Medgenics, Inc. is a biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. Medgenics currently has two products in development based on this technology: · EPODURE - producing erythropoietin (EPO) to treat anaemia · INFRADURE - producing interferon-alpha (IFN-alpha) to treat hepatitis C The Company has demonstrated proof of principle of the Biopump treatment procedure in a clinical trial using a short-acting version of EPODURE in anaemic patients. A long-acting version of EPODURE, designed to produce and deliver a therapeutic dose of EPO steadily for six months or more, is scheduled to enter Phase I/II trials in mid-2008. The Company plans to follow with clinical trials of INFRADURE in 2009. Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies, starting with EPODURE and INFRADURE. Beyond these, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US $87 billion by 2010. Other potential areas include multiple sclerosis (interferon-beta), haemophilia (Factor XIII), paediatric growth hormone deficiency (human growth hormone) and diabetes (insulin). Founded in 2000, Medgenics is a US-incorporated company with major operations in Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG). www.medgenics.com CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future operations. These statements relate to future events, prospects, developments and strategies. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur. This information is provided by RNS The company news service from the London Stock Exchange END NRAFKFKPQBKDCPK
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions